{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:33:51Z","timestamp":1793885631895,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T00:00:00Z","timestamp":1503878400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1245\/s10434-017-6033-x","type":"journal-article","created":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T18:03:36Z","timestamp":1503943416000},"page":"3640-3646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy"],"prefix":"10.1245","volume":"24","author":[{"given":"Florence","family":"Le Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano","family":"Gelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Dartigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Benhaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Go\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,28]]},"reference":[{"key":"6033_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jacl.2016.11.008","volume":"11","author":"P Poinsot","year":"2017","unstructured":"Poinsot P, Collardeau Frachon S, Restier L, et al. Childhood\/adult-onset lysosomal acid lipase deficiency: a serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases. J Clin Lipidol. 2017;11:167\u201377.","journal-title":"J Clin Lipidol."},{"key":"6033_CR2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF01225271","volume":"118","author":"M Markman","year":"1992","unstructured":"Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547\u201350.","journal-title":"J Cancer Res Clin Oncol."},{"key":"6033_CR3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s002920050340","volume":"20","author":"V Neumann","year":"1999","unstructured":"Neumann V, Muller KM, Fischer M. Peritoneal mesothelioma: incidence and etiology. Der Pathologe. 1999;20:169\u201376.","journal-title":"Der Pathologe."},{"key":"6033_CR4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/(SICI)1096-9098(199901)70:1<6::AID-JSO2>3.0.CO;2-X","volume":"70","author":"GH Eltabbakh","year":"1999","unstructured":"Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6\u201312.","journal-title":"J Surg Oncol."},{"key":"6033_CR5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","volume":"7","author":"PA Janne","year":"2005","unstructured":"Janne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40\u20136.","journal-title":"Clin Lung Cancer."},{"key":"6033_CR6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","volume":"64","author":"G Carteni","year":"2009","unstructured":"Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma: results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211\u20138.","journal-title":"Lung Cancer."},{"key":"6033_CR7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093\u2013100.","journal-title":"Ann Surg Oncol."},{"key":"6033_CR8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","volume":"65","author":"V Kepenekian","year":"2016","unstructured":"Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69\u201379.","journal-title":"Eur J Cancer."},{"key":"6033_CR9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","volume":"51","author":"C Hasovits","year":"2012","unstructured":"Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet. 2012;51:203\u201324.","journal-title":"Clin Pharmacokinet."},{"key":"6033_CR10","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1200\/JCO.2003.02.154","volume":"21","author":"RC Young","year":"2003","unstructured":"Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin: a gynecologic oncology group study. J Clin Oncol. 2003;21:4350\u20135.","journal-title":"J Clin Oncol."},{"key":"6033_CR11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","volume":"100","author":"JL Walker","year":"2006","unstructured":"Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100:27\u201332.","journal-title":"Gynecol Oncol."},{"key":"6033_CR12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001\u20137.","journal-title":"J Clin Oncol."},{"key":"6033_CR13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res."},{"key":"6033_CR14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176\u201381.","journal-title":"Semin Radiat Oncol."},{"key":"6033_CR15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29\u201342.","journal-title":"Ann Surg."},{"key":"6033_CR16","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1245\/s10434-007-9348-1","volume":"14","author":"D Elias","year":"2007","unstructured":"Elias D, Goere D, Blot F, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14:1818\u201324.","journal-title":"Ann Surg Oncol."},{"key":"6033_CR17","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/annonc\/mdh398","volume":"15","author":"D Elias","year":"2004","unstructured":"Elias D, Matsuhisa T, Sideris L, et al. Heated intraoperative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution, and tolerance. Ann Oncol. 2004;15:1558\u201365.","journal-title":"Ann Oncol."},{"key":"6033_CR18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267\u201372.","journal-title":"Ann Oncol."},{"key":"6033_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg."},{"key":"6033_CR20","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237\u201342.","journal-title":"J Clin Oncol."},{"key":"6033_CR21","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1\u201311.","journal-title":"Cancer Treat Reps."},{"key":"6033_CR22","doi-asserted-by":"crossref","unstructured":"Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;1:CD005340.","DOI":"10.1002\/14651858.CD005340.pub4"},{"key":"6033_CR23","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/ejso.2000.0983","volume":"26","author":"SR Pestieau","year":"2000","unstructured":"Pestieau SR, Stuart OA, Sugarbaker PH. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. Eur J Surg Oncol. 2000;26:696\u2013700.","journal-title":"Eur J Surg Oncol."},{"key":"6033_CR24","first-page":"890450","volume":"2012","author":"L Bijelic","year":"2012","unstructured":"Bijelic L, Stuart OA, Sugarbaker P. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Pract. 2012;2012:890450.","journal-title":"Gastroenterol Res Pract."},{"key":"6033_CR25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1096-9098(200102)76:2<106::AID-JSO1020>3.0.CO;2-E","volume":"76","author":"SR Pestieau","year":"2001","unstructured":"Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol. 2001;76:106\u201314.","journal-title":"J Surg Oncol."},{"key":"6033_CR26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ygyno.2011.07.031","volume":"123","author":"MS Henretta","year":"2011","unstructured":"Henretta MS, Anderson CL, Angle JF, Duska LR. It\u2019s not just for laparoscopy anymore: use of insufflation under ultrasound and fluoroscopic guidance by interventional radiologists for percutaneous placement of intraperitoneal chemotherapy catheters. Gynecol Oncol. 2011;123:342\u20135.","journal-title":"Gynecol Oncol."},{"key":"6033_CR27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/IGC.0b013e318234f7a8","volume":"22","author":"CR Greben","year":"2012","unstructured":"Greben CR, Goldstein GE, Lovecchio J, et al. Percutaneous insertion of peritoneal ports. Int J Gynecol Cancer. 2012;22:328\u201331.","journal-title":"Int J Gynecol Cancer."},{"key":"6033_CR28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1245\/s10434-015-4627-8","volume":"23","author":"M Faron","year":"2016","unstructured":"Faron M, Macovei R, Goere D, Honore C, Benhaim L, Elias D. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23:114\u20139.","journal-title":"Ann Surg Oncol."},{"key":"6033_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.suronc.2014.12.002","volume":"24","author":"J Hubert","year":"2015","unstructured":"Hubert J, Thiboutot E, Dube P, Cloutier AS, Drolet P, Sideris L. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis. Surg Oncol. 2015;24:41\u20136.","journal-title":"Surg Oncol."},{"key":"6033_CR30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejso.2012.03.001","volume":"38","author":"PH Cashin","year":"2012","unstructured":"Cashin PH, Graf W, Nygren P, Mahteme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol. 2012;38:509\u201315.","journal-title":"Eur J Surg Oncol."},{"key":"6033_CR31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63\u20138.","journal-title":"J Clin Oncol."},{"key":"6033_CR32","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jamcollsurg.2006.08.024","volume":"203","author":"RG Silva da","year":"2006","unstructured":"da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203:878\u201386.","journal-title":"J Am Coll Surg."},{"key":"6033_CR33","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-016-5143-1","volume":"23","author":"T Charrier","year":"2016","unstructured":"Charrier T, Passot G, Peron J, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23:2315\u201322.","journal-title":"Ann Surg Oncol."},{"key":"6033_CR34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejso.2010.04.005","volume":"36","author":"C Pomel","year":"2010","unstructured":"Pomel C, Ferron G, Lorimier G, et al. Hyperthermic intraperitoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma: results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol. 2010;36:589\u201393.","journal-title":"Eur J Surg Oncol."},{"key":"6033_CR35","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0399-8320(07)73964-7","volume":"31","author":"D Elias","year":"2007","unstructured":"Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007;31:784\u20138.","journal-title":"Gastroenterol Clin Biol."},{"key":"6033_CR36","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1245\/s10434-016-5487-6","volume":"24","author":"Y Yonemura","year":"2017","unstructured":"Yonemura Y, Ishibashi H, Hirano M, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal\/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2017;24:478\u201385.","journal-title":"Ann Surg Oncol."},{"key":"6033_CR37","first-page":"148420","volume":"2012","author":"Y Yonemura","year":"2012","unstructured":"Yonemura Y, Elnemr A, Endou Y, et al. Effects of neoadjuvant intraperitoneal\/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012;2012:148420.","journal-title":"Int J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-017-6033-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-6033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-6033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T14:00:32Z","timestamp":1509026432000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-017-6033-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,28]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["6033"],"URL":"https:\/\/doi.org\/10.1245\/s10434-017-6033-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,28]]}}}